TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Sep 12, 2022 09:00 JST
Source:
Eisai
Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies
TOKYO, Sep 12, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE trial/Study 305, Study 301 and Study304) evaluating the efficacy of eribulin mesylate (marketed as HALAVEN) versus other chemotherapies (Treatment of Physician's Choice [TPC], capecitabine, and vinorelbine, respectively) in patients living with metastatic breast cancer (mBC) whose tumors have low or no HER2 expression. These data were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22), held virtually and in-person in Paris, France from September 9-13, 2022.
The HER2-low breast cancer subtype is a newly defined subset consisting of tumors that would have previously been considered HER2-negative based on an immunohistochemistry (IHC) assay and an in situ hybridization (ISH) assay. HER2-low tumors express low amounts of the HER2 protein, but not enough to be considered HER2-positive. HER2-low is defined as an IHC of 1+ or 2 with a negative ISH. Of the approximate 288,000 new cases of female breast cancer expected to be diagnosed in the U.S. in 2022,(1) it is estimated that approximately 80-85% of patients would previously have been considered to have the HER2-negative subtype. Of those patients, about 60% would now be considered to have the HER2-low subtype.(2)
"In this post-hoc analysis, the outcomes seen in mBC patients whose tumors are considered HER2-low are consistent with the results of the three pivotal Phase 3 clinical trials," said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. "As the oncology community's understanding of mBC continues to evolve, it's important that we continue to evaluate the role of existing therapies in new contexts to contribute to the body of knowledge that is available to health care professionals."
(1) National Institutes of Health, National Cancer Institute website, "Cancer Stat Facts: Female Breast Cancer":
https://seer.cancer.gov/statfacts/html/breast.html
(2) U.S. FOOD & DRUG ADMINISTRATION website, "FDA Approves First Targeted Therapy for HER2-Low Breast Cancer": bit.ly/3xc0N7q
For more information, visit www.eisai.com/news/2022/pdf/enews202266pdf.pdf.
Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
September 26 2022 19:14 JST
Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
September 12 2022 14:37 JST
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
September 06 2022 09:42 JST
Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays
August 24 2022 15:18 JST
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care
August 09 2022 17:09 JST
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022
August 04 2022 08:25 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
August 04 2022 08:05 JST
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
July 26 2022 09:27 JST
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
July 26 2022 08:04 JST
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab
July 06 2022 09:12 JST
More Press release >>
Latest Press Release
Hitachi Astemo Receives EV e-Axle Orders from Honda, and will Further Expand its Electrification Business
Sep 26, 2022 20:25 JST
Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
Sep 26, 2022 20:14 JST
Fujitsu, Tohoku University embark on strategic alliance to realize 'Well-being Society'
Sep 26, 2022 12:18 JST
Honda and Idemitsu Hold 10th Anniversary Event of Rider Development Project at Grand Prix of Japan
Sep 26, 2022 10:06 JST
Seiryoku Zenyo, Jita Kyoei spirit is fundamental to Value Creation
Sep 24, 2022 07:00 JST
Toyota to End Vehicle Manufacturing in Russia
Sep 24, 2022 00:00 JST
TOYOTA GAZOO Racing Looks Forward to Another Returning Classic
Sep 23, 2022 11:11 JST
Hitachi Energy launches innovative oil-free and plug-and-play traction transformer
Sep 22, 2022 13:00 JST
Value Research Center at the Science Summit at UNGA77
Sep 22, 2022 12:00 JST
JCB presents STAR ISLAND Singapore Countdown Edition 2022-2023
Sep 21, 2022 19:00 JST
Fujitsu strengthens security practice with acquisition of leading New Zealand cybersecurity firm InPhySec
Sep 21, 2022 16:42 JST
Hitachi Energy to support major renewable electricity transmission between Canada and New York City
Sep 21, 2022 15:43 JST
Mitsubishi Motors' New Generation ASX for Europe Premieres Online
Sep 21, 2022 10:25 JST
Mitsubishi Motors' All-New Outlander Wins 2022 Australian Good Design Award
Sep 20, 2022 10:56 JST
F.C.C. TSR Honda France Fights Back to Win Second FIM Endurance World Championship Title
Sep 19, 2022 13:20 JST
Team Mitsubishi Ralliart Announces Team Lineup for Asia Cross Country Rally 2022 in November
Sep 19, 2022 11:04 JST
StraitsX announces native XSGD & XIDR on Polygon blockchain
Sep 16, 2022 16:00 JST
Hitachi Publishes "Hitachi Integrated Report 2022" and "Hitachi Sustainability Report 2022"
Sep 16, 2022 15:05 JST
Fujitsu and Phytocontrol to collaborate on offering food contaminant analysis service via Fujitsu Computing as a Service (CaaS)
Sep 16, 2022 11:10 JST
NEC Drives Expansion of All Optical Networks
Sep 15, 2022 17:24 JST
More Latest Release >>